Selective CB2 Drug Matched High-Dose CBD Effects for Colitis at a Fraction of the Dose | Research

The takeaway

In mouse colitis models, the synthetic CB2 agonist HU308 achieved the same therapeutic effect as CBD at 2.5 mg/kg vs 60 mg/kg, while both normalized gut hormone GLP-1 levels and reduced inflammation.

Gastroenterologists, IBD researchers, and cannabinoid therapy developers

HU308 matched CBD at 2.5 mg/kg vs 60 mg/kg

What the researchers found

CBD at 60 mg/kg (but not lower doses) significantly reduced colitis symptoms, inflammation, cytokine levels, and MPO activity. HU308 achieved comparable effects at just 2.5 mg/kg. Both treatments normalized GLP-1 levels, a biomarker of gut endocrine function. HU308 showed no observable toxicity.

Why it matters

CBD is widely used for inflammatory bowel conditions, but effective doses are high. Finding that a selective CB2 agonist achieves the same result at 1/24th the dose suggests more targeted cannabinoid therapies could be both more effective and safer for colitis.

The numbers in context

CBD effective dose: 60 mg/kg. HU308 effective dose: 2.5 mg/kg (24x lower). Both normalized DAI scores, colon inflammation, and GLP-1. DSS concentrations: 4% (acute), 1-2% (chronic). No toxicity observed with HU308.

How the study worked

Mouse models of DSS-induced colitis mimicking acute (4% DSS) and chronic (1-2% DSS) ulcerative colitis. Mice treated with CBD at multiple doses or HU308. Disease activity index, colon inflammation, cytokines, MPO activity, ammonia levels, and GLP-1 expression were measured.

What this study cannot tell us

Mouse colitis model may not fully represent human ulcerative colitis. HU308 is a synthetic compound not available as a consumer product. Only one dose of HU308 was tested. Long-term effects and safety in chronic dosing are unknown.

How to read the evidence

Well-designed preclinical study with dose comparison across both acute and chronic models, but animal findings need human validation.

When this study was published

2024 study

The bigger picture

The GLP-1 normalization finding is novel and connects cannabinoid therapy to gut endocrine function, a pathway increasingly recognized in GI disease. This could provide a biomarker for treatment response and a mechanistic link between the endocannabinoid and gut hormone systems.

Questions still open

Would HU308 or similar CB2 agonists work in human colitis? Could GLP-1 levels serve as a biomarker to guide cannabinoid dosing? Why was CBD only effective at the highest dose tested?

Common questions

Can cannabinoids help with colitis?

In mice, both CBD (at high doses) and a targeted CB2 receptor drug significantly reduced colitis inflammation and symptoms. The CB2 drug achieved the same effect at 1/24th the CBD dose.

Why might targeted cannabinoid drugs be better than CBD for gut inflammation?

This study showed a CB2-selective drug matched CBD efficacy at a much lower dose, potentially reducing off-target effects while achieving the same anti-inflammatory benefits.

Read the original research

Comprehensive Assessment of Cannabidiol and HU308 in Acute and Chronic Colitis Models: Efficacy, Safety, and Mechanistic Innovations.

Cells, 13(23)

View on PubMed ↗Publisher’s paper ↗

Citation

Thapa, Dinesh; Patil, Mohan; Warne, Leon N; Carlessi, Rodrigo; Falasca, Marco. (2024). Comprehensive Assessment of Cannabidiol and HU308 in Acute and Chronic Colitis Models: Efficacy, Safety, and Mechanistic Innovations.. Cells, 13(23). https://doi.org/10.3390/cells13232013